Andrew Sandford

A microbiologist by education, Andrew Sandford has been building businesses around innovative offerings for over 20 years. In joining Anzu Partners as an Executive in Residence, Andrew will work with Anzu portfolio companies to develop strategies and commercial relationships, participate in diligence of prospective portfolio companies and work with the Anzu investment team in developing investment theses. 

Prior to joining Anzu, Andrew served as Vice President of Global Business Development, Biologics, for Catalent Pharma Solutions, a leading global provider of advanced services and technologies for drugs, biologics, and consumer health products. Earlier in his career, Andrew served as Vice President of Business Development for Selexis, Inc. where he established the U.S. subsidiary and was responsible for global transactional and strategic value creation. Andrew also worked for Cambrex Biopharma, which was latterly acquired by Lonza Biologics. He also spent nearly 10 years in Dow Chemical’s Ventures unit where he established and launched the highly successful Pfenex business unit.

He holds several professional leadership certifications, and is a graduate of the State University of New York College of Plattsburgh.